Q3 EPS Estimate for Cooper Companies Reduced by Analyst

The Cooper Companies, Inc. (NASDAQ:COO) – Analysts at Zacks Research cut their Q3 2026 earnings per share (EPS) estimates for Cooper Companies in a research note issued on Wednesday, June 24th. Zacks Research analyst Team now forecasts that the medical device company will post earnings of $1.11 per share for the quarter, down from their prior forecast of $1.17. The consensus estimate for Cooper Companies’ current full-year earnings is $4.63 per share. Zacks Research also issued estimates for Cooper Companies’ Q4 2026 earnings at $1.19 EPS, FY2026 earnings at $4.61 EPS, Q1 2027 earnings at $1.17 EPS, Q2 2027 earnings at $1.20 EPS, Q3 2027 earnings at $1.22 EPS, Q4 2027 earnings at $1.32 EPS, FY2027 earnings at $4.91 EPS, Q1 2028 earnings at $1.28 EPS, Q2 2028 earnings at $1.32 EPS and FY2028 earnings at $5.42 EPS.

Cooper Companies (NASDAQ:COO) last released its earnings results on Thursday, June 4th. The medical device company reported $1.21 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.11. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same quarter in the prior year, the firm posted $0.96 earnings per share. The company’s quarterly revenue was up 7.9% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS.

Several other research analysts have also weighed in on COO. KeyCorp reissued a “sector weight” rating on shares of Cooper Companies in a research note on Friday, June 5th. Barclays increased their target price on shares of Cooper Companies from $98.00 to $103.00 and gave the stock an “overweight” rating in a report on Friday, March 6th. Stifel Nicolaus decreased their price target on shares of Cooper Companies from $95.00 to $85.00 and set a “buy” rating for the company in a report on Friday, June 5th. BNP Paribas Exane lowered their price objective on shares of Cooper Companies from $95.00 to $92.00 and set an “outperform” rating for the company in a research report on Monday, June 8th. Finally, Citigroup reaffirmed a “neutral” rating and set a $69.00 price objective (down from $80.00) on shares of Cooper Companies in a research note on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $81.31.

Cooper Companies Stock Performance

Shares of COO stock opened at $68.83 on Thursday. The stock has a market cap of $13.42 billion, a PE ratio of 58.33, a price-to-earnings-growth ratio of 1.73 and a beta of 0.87. The stock has a 50-day moving average of $64.11 and a 200-day moving average of $73.74. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.27 and a quick ratio of 0.78. Cooper Companies has a one year low of $58.89 and a one year high of $89.83.

Institutional Investors Weigh In On Cooper Companies

Several institutional investors have recently bought and sold shares of COO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Cooper Companies by 48.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company’s stock worth $1,890,000 after purchasing an additional 7,363 shares during the last quarter. First Trust Advisors LP raised its stake in shares of Cooper Companies by 115.8% during the 2nd quarter. First Trust Advisors LP now owns 136,334 shares of the medical device company’s stock worth $9,702,000 after purchasing an additional 73,165 shares in the last quarter. Cresset Asset Management LLC acquired a new stake in shares of Cooper Companies in the 2nd quarter valued at approximately $291,000. Cerity Partners LLC grew its stake in shares of Cooper Companies by 4.4% in the second quarter. Cerity Partners LLC now owns 17,870 shares of the medical device company’s stock valued at $1,272,000 after buying an additional 757 shares in the last quarter. Finally, Daiwa Securities Group Inc. increased its holdings in Cooper Companies by 2.8% during the second quarter. Daiwa Securities Group Inc. now owns 35,839 shares of the medical device company’s stock worth $2,551,000 after buying an additional 973 shares during the last quarter. Institutional investors own 24.39% of the company’s stock.

Key Stories Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Zacks Research lifted Cooper Companies’ FY2026 EPS estimate to $4.61 from $4.58, suggesting slightly better near-term earnings expectations. NASDAQ:COO overview
• Positive Sentiment: The analyst also raised FY2027 EPS to $4.91 from $4.89 and FY2028 EPS to $5.42 from $5.34, reinforcing a stronger growth trajectory for the medical device maker. NASDAQ:COO overview
• Positive Sentiment: Quarterly estimates were nudged higher in several periods, including Q1 2027, Q2 2027, Q2 2028, and Q4 2027, which may support sentiment that earnings momentum remains intact. NASDAQ:COO overview
• Neutral Sentiment: Not all forecasts were higher: Zacks trimmed its Q3 2026 and Q4 2026 EPS estimates and also lowered Q3 2027, which adds a small note of caution around near-term timing. NASDAQ:COO overview

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.